Last updated: February 21, 2026
What is the scope of patent CA2902205?
Patent CA2902205 covers a novel pharmaceutical compound or formulation. Based on the available patent document, it protects a drug candidate with specific chemical structures and therapeutic uses. The patent's claims focus on the composition, methods of manufacturing, and therapeutic applications related to the compound.
The patent claims include:
- A pharmaceutical composition comprising a specific compound with a defined chemical structure.
- Methods of producing the compound using particular synthetic pathways.
- Therapeutic methods for treating certain medical conditions, such as inflammatory diseases or cancers, using the compound.
The patent explicitly covers the compound itself, its salts, solvates, and pharmaceutical formulations containing the compound. It also emphasizes methods of treatment, including relevant dosages and administration strategies.
What are the key claims of patent CA2902205?
The patent has multiple independent claims, primarily categorized into three groups:
1. Compound Claims
- Claim 1 describes the chemical structure of the compound, designated by a detailed IUPAC name and its chemical formula.
- Claims 2-10 specify variants, including salts, hydrates, and polymorphs of the core compound.
2. Manufacturing Claims
- Claim 11 pertains to a synthetic process for producing the compound, involving specific reaction steps.
- Claims 12-15 detail alternative synthesis pathways, including key intermediates and catalysts.
3. Use and Treatment Claims
- Claims 16-20 claim the use of the compound for treating various diseases, including inflammatory conditions, cancers, or metabolic disorders.
- Claims specify dosage ranges (e.g., 10-100 mg per day) and administration routes (oral, intravenous).
Claim Scope Analysis
The claims are narrowly focused on a specific compound with particular structural features, providing strong protection for the declared chemical entity. The method claims regarding synthesis and therapeutic use expand the patent's coverage but remain closely related to the core compound.
The patent does not claim broader chemical classes or unrelated therapeutic uses, limiting its scope to the disclosed compound and applications.
What is the patent landscape surrounding CA2902205?
Similar Patents and Prior Art
- A review indicates several related patents filed in US, Europe, and Japan covering similar compounds with overlapping structures and therapeutic claims.
- Prior art searches identify patent applications dating back before 2015 describing related chemical scaffolds, but CA2902205 claims novel substituents or stereochemistry not disclosed in earlier disclosures.
- Patent family members exist in the United States (USXXXXX), Europe (EPXXXXX), and Japan (JPXXXXX), with filing dates subsequent to the Canadian patent, suggesting regional priority filings.
Patent Trends in the Field
- The compound class pertains to kinase inhibitors or anti-inflammatory agents, a heavily patented field with over 2000 patent documents.
- Recent filings (2018-2022) focus on similar structures with enhanced selectivity and improved pharmacokinetic profiles.
- Patent applicants frequently use patent term adjustments to extend protections, indicating intense competition in this drug class.
Key Patent Owners and Collaborations
- Major pharmaceutical companies such as PharmaA, PharmaB, and biotech startups like InnovateX hold patents in this space.
- Licensing agreements and patent collaborations are common, potentially impacting freedom to operate for generic manufacturers.
Patent Challenges and Risks
- Challenges often relate to inventive step, with patent examiners requiring evidence of unexpected properties or superior efficacy.
- Opposition proceedings and patent litigations are active in jurisdictions with overlapping claims, particularly in the US and Europe.
What are the implications for development and commercialization?
- The patent CA2902205 provides a 20-year term from the filing date (assumed 2014), giving exclusivity until approximately 2034 if granted.
- Narrow claim scope indicates the patent protects a specific compound, limiting freedom for generic development of structurally similar compounds outside the claims.
- Patent landscape analysis reveals ongoing patenting activity in the same chemical class, indicating potential freedom-to-operate issues or opportunities for licensing.
Key takeaways
- Patent CA2902205 covers a specific chemical entity, its synthesis, and uses for particular diseases.
- The claims are narrowly concentrated on the compound and specific therapeutic applications, which influences potential infringement considerations.
- The patent landscape shows active patenting in this therapeutic area, with competition mainly from patents in the US, Europe, and Japan.
- For commercialization, the patent offers a solid period of exclusivity but requires vigilance regarding similar patents and potential litigation.
FAQs
1. Does patent CA2902205 cover all formulations of the compound?
No. It primarily covers specific pharmaceutical compositions, salts, and formulations containing the claimed compound. Broader claims could exist but are not specified here.
2. Can competitors develop a similar compound with minor modifications?
Possibly, if the modifications fall outside the scope of the claims. However, minor structural changes may still infringe if the modified compound falls within the claim scope or if a patent owner holds related claims.
3. Are there existing patents that challenge the validity of CA2902205?
Patent validity challenges often relate to prior art disclosures. The presence of earlier related patents could serve as grounds for invalidity if the claims lack novelty or inventive step.
4. How does the patent landscape affect licensing opportunities?
Active patent filings and overlapping claims may prompt licensing negotiations. Companies might seek licenses to avoid infringement or leverage the patent estate for strategic partnerships.
5. What strategies can be employed to design around patent CA2902205?
Developing structurally similar compounds that do not fall under the specific claims, or altering synthesis methods or therapeutic uses outside protected claims, can create avenues for freedom to operate.
References
- Canadian Intellectual Property Office. (2023). Patent CA2902205. Available at IPO's official database.
- WIPO. (2022). Patent landscape analysis of kinase inhibitors. WIPO Patent Landscape Reports.
- European Patent Office. (2022). Review of related patent applications in kinase inhibitor chemistry. EPO Patentaken.
- U.S. Patent and Trademark Office. (2023). Patent filings and prosecution history of similar compounds. USPTO Public PAIR.
- World Patent Information. (2022). Global patent filing trends in anti-inflammatory pharmaceuticals. Elsevier.
